ITGAM and neoplasm: In brain tumor xenograft models, metronomic cyclophosphamide (Q6day cycle) activated anti-tumor immunity (blocked by axitinib and DC101), which is associated with tumor regression, and decreased CD11b+GR1+ reservoirs in bone marrow and spleen [158,159].